CollPlant Biotechnologies (CLGN)
(Delayed Data from NSDQ)
$4.68 USD
-0.11 (-2.30%)
Updated Jul 25, 2024 03:51 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Income Statements
Fiscal Year end for CollPlant Biotechnologies Ltd Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 11 | 0 | 16 | 6 | 2 |
Cost Of Goods | 2 | 0 | 2 | 3 | 2 |
Gross Profit | 9 | 0 | 14 | 3 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 17 | 14 | 9 | 8 |
Income After Depreciation & Amortization | -8 | -17 | 0 | -6 | -8 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 3 |
Pretax Income | -7 | -17 | 0 | -6 | -11 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -7 | -17 | 0 | -6 | -11 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -7 | -17 | 0 | -6 | -11 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -16 | 1 | -5 | -7 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -8 | -17 | 0 | -6 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 11.39 | 11.03 | 11.97 | 6.89 | 4.99 |
Diluted EPS Before Non-Recurring Items | -0.62 | -1.53 | 0.02 | -0.84 | -1.29 |
Diluted Net EPS (GAAP) | -0.62 | -1.53 | 0.02 | -0.84 | -2.23 |
Fiscal Year end for CollPlant Biotechnologies Ltd Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.10 | 0.30 | 0.04 | 10.18 |
Cost Of Goods | NA | 0.55 | 0.77 | 0.28 | 0.62 |
Gross Profit | NA | -0.45 | -0.47 | -0.24 | 9.57 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.89 | 4.59 | 4.37 | 3.89 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.34 | -5.06 | -4.61 | 5.68 |
Non-Operating Income | NA | 0.13 | 0.18 | 0.23 | 0.09 |
Interest Expense | NA | 0.00 | -0.20 | 0.00 | 0.00 |
Pretax Income | NA | -4.20 | -4.69 | -4.38 | 5.76 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.20 | -4.69 | -4.38 | 5.76 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.20 | -4.69 | -4.38 | 5.76 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 11.45 | 11.16 | 11.44 | 11.78 |
Diluted EPS Before Non-Recurring Items | NA | -0.37 | -0.42 | -0.38 | 0.49 |
Diluted Net EPS (GAAP) | NA | -0.37 | -0.40 | -0.38 | 0.49 |